Engineering Evonik to Invest 176-Million-Dollars for Building New Methyl Mercaptan Plant in USA

Source: Press release

Evonik has plans to construct a new methyl mercaptan plant at its Mobile site in Alabama, USA. With this move, the company aims to strengthen its world-scale methionine production hub in the country.

Related Vendors

The plant is scheduled to come on stream in the second half of 2024.
The plant is scheduled to come on stream in the second half of 2024.
(Source: Pixabay)

Essen/Germany – Evonik will build a methyl mercaptan plant at its site in Mobile, Alabama in the U.S. Methyl mercaptan is an intermediate in the production of Metamino (DL-methionine) and is currently sourced from third parties. This backward integration step strengthens Evonik's site in Mobile as a global, best-in-class methionine hub for reliable and cost-optimized supply to North and South American markets. The plant is scheduled to come on stream in the second half of 2024. The investment budget of the project is approximately 176 million dollars over three years.

"The new methyl mercaptan plant in Mobile is another important step in the consistent implementation of our global methionine asset strategy," says Johann-Caspar Gammelin, head of Evonik's Nutrition & Care division. "We are securing our cash flow from the methionine business to finance our growth with system solutions in Nutrition & Care."

PROCESS Insights 2020-05
Challenges for EPC Contractors

With an influx of largescale petrochemical construction projects, EPC Contractors will have to be confronted with challenges such as finding enough capacity and quality of construction manpower, delayed permits etc. which require an EPC strategy to stay competitive in this ever-growing market.

This 12-page Process Insight will discuss the current changes in the EPC business and the impact of these changes on EPC projects. Besides the effect of the Coronavirus as well as the current oil price crash on the contracting industry will also be analyzed and an outlook for the industry will be given.

The core of the methionine asset strategy are the three world-class production hubs: Mobile, Antwerp (Belgium) and Singapore. Together these hubs serve the expanding global market for DL-methionine. As part of the asset strategy, the smallest methionine plant at the German site in Wesseling was discontinued in 2021. At the same time the European Metamino Verbund was strengthened by investment in intermediates at this site.

The global methionine production hubs in Antwerp and Singapore are already fully backward integrated. This contributes – just like the present investment in Mobile – to improved supply security and a market-leading cost position. It also facilitates future and highly efficient debottlenecking over the next years.

"In the market we stand for quality, superior supply reliability, and a high level of safety and technology standards in our assets. The backward integration in Mobile eliminates transportation of hazardous chemicals and shows our continued commitment to responsible care and business sustainability. This ultimately positions us even better as a reliable partner for our customers in the Americas," says Dr. Emmanuel Auer, head of the Animal Nutrition business line at Evonik.

The investment is also a building block of the division's sustainability strategy: it will reduce the carbon footprint of DL-methionine from Mobile by about seven percent. More than 25,000 metric tons of CO2 equivalents can be saved each year.